期刊
PHARMACEUTICS
卷 13, 期 12, 页码 -出版社
MDPI
DOI: 10.3390/pharmaceutics13122196
关键词
cell therapies; hyaluronic acid; hydrogels; progenitor cells; regenerative medicine; stabilization; tendinopathies; viscoelasticity
资金
- S.A.N.T.E Foundation
- Sandoz Family Foundation
- Service of Promotion of the Economy and Innovation of the Canton of Vaud (SPEI)
- Vaud Cantonal Law on Economic Development [LADE 20-411]
This study experimentally characterized formulations containing progenitor tenocyte-derived APIs and hyaluronan, confirming their potential applications in treating tendon disorders with advantages in physical and chemical stability, antioxidant properties, and injectability.
Cultured progenitor cells and derivatives have been used in various homologous applications of cutaneous and musculoskeletal regenerative medicine. Active pharmaceutical ingredients (API) in the form of progenitor cell derivatives such as lysates and lyophilizates were shown to retain function in controlled cellular models of wound repair. On the other hand, hyaluronan-based hydrogels are widely used as functional vehicles in therapeutic products for tendon tissue disorders. The aim of this study was the experimental characterization of formulations containing progenitor tenocyte-derived APIs and hyaluronan, for the assessment of ingredient compatibility and stability in view of eventual therapeutic applications in tendinopathies. Lyophilized APIs were determined to contain relatively low quantities of proteins and growth factors, while being physicochemically stable and possessing significant intrinsic antioxidant properties. Physical and rheological quantifications of the combination formulas were performed after hydrogen peroxide challenge, outlining significantly improved evolutive viscoelasticity values in accelerated degradation settings. Thus, potent effects of physicochemical protection or stability enhancement of hyaluronan by the incorporated APIs were observed. Finally, combination formulas were found to be easily injectable into ex vivo tendon tissues, confirming their compatibility with further translational clinical approaches. Overall, this study provides the technical bases for the development of progenitor tenocyte derivative-based injectable therapeutic products or devices, to potentially be applied in tendinous tissue disorders.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据